Warnings that stopping Gilenya® could make multiple sclerosis worse: industry news round-up

Written by Sharon Salt, Editor

In this week’s industry news round-up we cover the latest headlines on multiple sclerosis, glioblastoma and illegal marketing of dietary supplements containing antidepressants. Find out more about our selection of the highlights below. Our selection of the highlights includes: BrainStorm Cell Therapeutics submits IND for NurOwn® in progressive multiple sclerosis TRC102 and Temodar® fail to meet primary endpoint in Phase II glioblastoma trial Warnings that stopping Gilenya® could make multiple sclerosis worse Illegal marketing of dietary supplements containing antidepressants receives US FDA warning BrainStorm Cell Therapeutics submits IND for NurOwn® in progressive multiple sclerosis BrainStorm Cell Therapeutics (NY, USA) has...

To view the full article, please register now for access

It's completely free